Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.

@article{Hatsukami2005SafetyAI,
  title={Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.},
  author={Dorothy K. Hatsukami and Stephen Rennard and Douglas E. Jorenby and Michael Fiore and Joseph Koopmeiners and Arjen de Vos and Gary Horwith and Paul R. Pentel},
  journal={Clinical pharmacology and therapeutics},
  year={2005},
  volume={78 5},
  pages={456-67}
}
Immunotherapy is a novel potential treatment for nicotine addiction. The aim of this study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior. Smokers (N = 68) were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the nicotine vaccine (50, 100, or 200 microg) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38 weeks. Results showed that the nicotine vaccine… CONTINUE READING